Innovative CKD management: AstraZeneca’s Zibotentan/Dapagliflozin advances to Phase III
Recent findings from the ZENITH-CKD Phase IIb trial, conducted by AstraZeneca, have demonstrated a significant decrease in albuminuria among CKD patients treated with a combination ... Read More
AstraZeneca, Cellectis join forces to boost cell, gene therapy innovations
AstraZeneca announced a strategic collaboration and investment agreement with Cellectis, a leader in clinical-stage biotechnology. This partnership, valued initially at $105 million, signifies a substantial ... Read More
ENHERTU receives EU approval for advanced non-small cell lung cancer
The European Union (EU) has given its nod to ENHERTU (trastuzumab deruxtecan) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) ... Read More
AstraZeneca and Daiichi Sankyo’s Enhertu recommended for EU approval
AstraZeneca and Daiichi Sankyo's Enhertu has been recommended for approval in the European Union (EU) for the treatment of adult patients with advanced non-small cell ... Read More
AstraZeneca’s Fasenra meets primary endpoint in MANDARA Phase 3 trial for EGPA
AstraZeneca's Fasenra met its primary endpoint in the MANDARA Phase III trial, offering a monthly treatment option for eosinophilic granulomatosis with polyangiitis (EGPA) patients. Fasenra ... Read More
China’s NMPA expands AstraZeneca’s Forxiga use as heart failure treatment
China's National Medical Products Administration (NMPA) has approved AstraZeneca's Forxiga (dapagliflozin) for diminishing the risk of cardiovascular fatalities and hospitalizations in adults diagnosed with symptomatic ... Read More
Enhertu shows promising results in DESTINY-PanTumor02 Phase 2 trial
The DESTINY-PanTumor02 Phase II trial revealed high-level results for AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), showcasing clinically meaningful progression-free survival (PFS) and overall survival ... Read More
Alexion’s Soliris approved for paediatric myasthenia gravis treatment in EU
Soliris (eculizumab), the first and only targeted therapy approved for the treatment of paediatric patients with refractory generalised myasthenia gravis (gMG), from Alexion, AstraZeneca Rare ... Read More
AstraZeneca’s Alexion to boost rare disease commitment with Pfizer’s gene therapy programs
Alexion, a subdivision of AstraZeneca focusing on rare diseases, has announced its definitive purchase and licensing agreement for a portfolio of preclinical gene therapy programmes ... Read More
AstraZeneca, Daiichi Sankyo’s Enhertu approved for breast cancer in China
The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in ... Read More